相关实验视频

Updated: May 31, 2025

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

选择性使用pre-miR-1307对血管新生产生失调,并影响乳腺癌的攻击性

Oyku Ece Sumer^1,2, Korbinian Schelzig^1,2, Janine Jung^1,2

¹Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, Heidelberg, 69120, Germany.

|January 24, 2025

概括

微RNAs (miRNAs) 与乳腺癌有关. 这项研究揭示了miR-1307-5p抑制瘤生长和血管生成,为乳腺癌提供潜在的治疗点.

科学领域:

分子生物学分子生物学
在瘤学瘤学.
遗传学是一个遗传学.

背景情况:

乳腺癌仍然是女性癌症死亡的主要原因.
微RNA (miRNA) 放松调节在乳腺癌中很常见,影响瘤生物学.
前微RNA-1307及其成熟形式在乳腺癌中的特定作用以前未被研究.

研究的目的:

调查前微型RNA-1307及其衍生miRNAs在乳腺癌中的作用.
阐明miR-1307-5p对乳腺癌进展和血管生成的功能影响.
探索乳腺癌中miRNA手臂选择的调节机制.

主要方法:

在人类乳腺癌组织中分析miRNA表达.
在乳腺癌细胞系中过度表达pre-miR-1307.
在体内对异种移植生长和血管生成的评估.
分泌组分析和内皮细胞生长试验.
在miRNA表达和瘤特征之间的相关性分析.

主要成果:

从miR-1307前的三个成熟的miRNA物种在乳腺癌组织中显著上调.
前-miR-1307的过度表达减少了瘤生长和血管生成.
miR-1307-5p的过度表达改变了癌细胞的分泌物,并抑制了内皮细胞的发芽.
miR-1307-5p的表达与瘤中的内皮细胞分数相反相关,表明它具有抗血管性作用.
协调调节miRNA臂的使用表明一个共同的潜在机制.

结论:

miR-1307-5p通过降低乳腺癌中的血管生成来表现出抑制瘤的活性,抵消瘤性miR-1307-3p.
这些发现强调了miRNA手臂选择调节在癌症中的重要性.
鉴定的机制可能为针对癌症治疗中miRNA平衡的新疗法策略铺平道路.

关键词:

血管新生的产生.乳腺癌是什么? 乳腺癌是什么?它的同位素是Rs.转移转移转移转移选择性使用miRNA的手臂.在 miR-1307 系统中,这是一个miRNA手臂开关.这就是miRNAs.

更多相关视频

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...